Marcus Butler

Company: University Health Network

Job title: Clinician Investigator

Bio:

Dr. Marcus Butler is a physician investigator with a strong interest in research and clinical medicine. He is dedicated to successfully translating novel immune-based therapies to patients. He received his MD from Yale University and was trained in Internal Medicine at Johns Hopkins Hospital. He then completed Hematology/Oncology training at Dana-Farber/Partners CancerCare, Harvard Medical School. After serving on the Dana-Farber staff, he joined the Department of Medical Oncology and Hematology at the Princess Margaret Cancer Centre in 2012. He is the Multidisciplinary Disease Site Lead for Melanoma/Skin Oncology at Princess Margaret. He is a member of the Princess Margaret Tumor Immunotherapy Program and is an Associate Professor in the Departments of Medicine and Immunology at the University of Toronto. He is Co-chair for the Melanoma and Skin Cancer Site at the CCTG (Canadian Cancer Trials Group). Dr. Butler has been involved in the early development of several important immune-based therapies for cancer, including adoptive cell therapy and immunomodulators including immune checkpoint blockade. As clinical director of the Princess Margaret Centre for Integrative Immune Analysis, he is investigating the immunologic impact of immune-based therapies as part of standard of care and in clinical trials. 

Seminars:

Understanding Global Approvals & Implementation of TIL Therapies 4:00 pm

Highlighting the process of implementing TIL therapies within publicly funded healthcare systems through health technology assessments Comparing regulatory approval pathways across countries to inform trial design and global strategy Addressing the role of academic institutions in sustaining TIL research amid industry and funding instabilityRead more

day: Conference Day Two PM

Panel Discussion: Navigating Regulatory Insights for Global Clinical Adoption of TIL Therapies 4:30 pm

Examining the spectrum of regulatory flexibility from IND filing to BLA submission and its impact on TIL therapies Highlighting the differences in regulatory approaches in China and other regions, and their implications for clinical trials and patient access Assessing the feasibility of expanding TIL therapies beyond North America to increase patient accessibilityRead more

day: Conference Day Two PM